FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210715759> ?p ?o ?g. }

• W4210715759 abstract "Background The optimal treatment of superficial thrombophlebitis (ST) of the legs remains poorly defined. While improving or relieving the local painful symptoms, treatment should aim at preventing venous thromboembolism (VTE), which might complicate the natural history of ST. This is the second update of a review first published in 2007. Objectives To assess the efficacy and safety of topical, medical, and surgical treatments in patients presenting with ST of the legs. Search methods For this update, the Cochrane Peripheral Vascular Diseases Group Trials Search Co‐ordinator searched the Specialised Register (last searched November 2012) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 11). We handsearched the reference lists of relevant papers and conference proceedings. Selection criteria Randomised controlled trials (RCTs) evaluating topical, medical, and surgical treatments for ST of the legs that included participants with a clinical diagnosis of ST of the legs or objective diagnosis of a thrombus in a superficial vein. Data collection and analysis Two authors assessed the trials for inclusion in the review, extracted the data, and assessed the quality of the studies. Data were independently extracted from the included studies and any disagreements resolved by consensus. Main results We identified four additional trials (941 patients), so this update considered 30 studies involving 6462 participants with ST of the legs.Treatment ranged from fondaparinux, low molecular weight heparin (LMWH), unfractionated heparin (UFH), non‐steroidal anti‐inflammatory agents (NSAIDs), topical treatment, oral treatment, intramuscular treatment, and intravenous treatment to surgery. Only a minority of trials compared treatment with placebo rather than an alternative treatment, none evaluated the same treatment comparisons on the same study outcomes (which precluded meta‐analysis), and many of the studies were small and of poor quality. In one large, placebo‐controlled RCT of 3002 patients, subcutaneous fondaparinux was associated with a significant reduction in symptomatic VTE (RR 0.15; 95% CI 0.04 to 0.50), ST extension (RR 0.08; 95% CI 0.03 to 0.22), and ST recurrence (RR 0.21; 95% CI 0.08 to 0.54) with comparable rates of major bleeding (RR 0.99; 95% CI 0.06 to 15.86) relative to placebo. In a further placebo‐controlled trial, both prophylactic and therapeutic doses of LMWH (RR 0.44; 95% CI 0.26 to 0.74 and RR 0.46; 95% CI 0.27 to 0.77, respectively) and NSAIDs (RR 0.46; 95% CI 0.27 to 0.78) reduced the extension and recurrence of ST in comparison to placebo, with no significant effects on symptomatic VTE nor major bleeding. Overall, topical treatments improved local symptoms compared with placebo but no data were provided on the effects on VTE and ST extension. Surgical treatment combined with elastic stockings was associated with a lower VTE rate and ST progression compared with elastic stockings alone. However, the majority of studies that compared different oral treatment, topical treatment, or surgery did not report VTE, ST progression, adverse events, or treatment side effects. Authors' conclusions Prophylactic dose fondaparinux given for 45 days appears to be a valid therapeutic option for ST of the legs. The evidence on oral treatments, topical treatment, or surgery is too limited and does not inform clinical practice about the effects of these treatments in terms of VTE and ST progression. Further research is needed to assess the role of the new oral direct thrombin and activated factor‐X inhibitors, LMWH, and NSAIDs; the optimal doses and duration of treatment; and whether a combination therapy may be more effective than single treatment. Adequately designed and conducted studies are required to clarify the role of topical and surgical treatments." @default.
• W4210715759 created "2022-02-08" @default.
• W4210715759 creator A5000735539 @default.
• W4210715759 creator A5019746556 @default.
• W4210715759 creator A5035786262 @default.
• W4210715759 date "2013-04-30" @default.
• W4210715759 modified "2023-09-26" @default.
• W4210715759 title "Treatment for superficial thrombophlebitis of the leg" @default.
• W4210715759 cites W1550326108 @default.
• W4210715759 cites W1781851783 @default.
• W4210715759 cites W181416742 @default.
• W4210715759 cites W1971501970 @default.
• W4210715759 cites W1973758476 @default.
• W4210715759 cites W1973904493 @default.
• W4210715759 cites W1976178781 @default.
• W4210715759 cites W1982824664 @default.
• W4210715759 cites W1997889941 @default.
• W4210715759 cites W2000043248 @default.
• W4210715759 cites W2013067110 @default.
• W4210715759 cites W2033890227 @default.
• W4210715759 cites W2033902432 @default.
• W4210715759 cites W2036740 @default.
• W4210715759 cites W2042065453 @default.
• W4210715759 cites W2050345169 @default.
• W4210715759 cites W2051213580 @default.
• W4210715759 cites W2051358961 @default.
• W4210715759 cites W2062078665 @default.
• W4210715759 cites W2067471052 @default.
• W4210715759 cites W2081716422 @default.
• W4210715759 cites W2085384014 @default.
• W4210715759 cites W2087539681 @default.
• W4210715759 cites W2088393297 @default.
• W4210715759 cites W2092402575 @default.
• W4210715759 cites W2095766682 @default.
• W4210715759 cites W2114766505 @default.
• W4210715759 cites W2116451043 @default.
• W4210715759 cites W2121115028 @default.
• W4210715759 cites W2125435699 @default.
• W4210715759 cites W2129180601 @default.
• W4210715759 cites W2133782718 @default.
• W4210715759 cites W2141867316 @default.
• W4210715759 cites W2143281433 @default.
• W4210715759 cites W2156185381 @default.
• W4210715759 cites W2165010366 @default.
• W4210715759 cites W2568955214 @default.
• W4210715759 cites W4210594842 @default.
• W4210715759 cites W4245655207 @default.
• W4210715759 cites W4324113849 @default.
• W4210715759 cites W607435145 @default.
• W4210715759 doi "https://doi.org/10.1002/14651858.cd004982.pub5" @default.
• W4210715759 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23633322" @default.
• W4210715759 hasPublicationYear "2013" @default.
• W4210715759 type Work @default.
• W4210715759 citedByCount "25" @default.
• W4210715759 countsByYear W42107157592014 @default.
• W4210715759 countsByYear W42107157592015 @default.
• W4210715759 countsByYear W42107157592016 @default.
• W4210715759 countsByYear W42107157592017 @default.
• W4210715759 countsByYear W42107157592018 @default.
• W4210715759 countsByYear W42107157592019 @default.
• W4210715759 countsByYear W42107157592020 @default.
• W4210715759 countsByYear W42107157592022 @default.
• W4210715759 crossrefType "journal-article" @default.
• W4210715759 hasAuthorship W4210715759A5000735539 @default.
• W4210715759 hasAuthorship W4210715759A5019746556 @default.
• W4210715759 hasAuthorship W4210715759A5035786262 @default.
• W4210715759 hasConcept C126322002 @default.
• W4210715759 hasConcept C141071460 @default.
• W4210715759 hasConcept C142724271 @default.
• W4210715759 hasConcept C168563851 @default.
• W4210715759 hasConcept C197934379 @default.
• W4210715759 hasConcept C204787440 @default.
• W4210715759 hasConcept C27081682 @default.
• W4210715759 hasConcept C2776149422 @default.
• W4210715759 hasConcept C2776301958 @default.
• W4210715759 hasConcept C2776877702 @default.
• W4210715759 hasConcept C2777475103 @default.
• W4210715759 hasConcept C2778661090 @default.
• W4210715759 hasConcept C2779161974 @default.
• W4210715759 hasConcept C2779324797 @default.
• W4210715759 hasConcept C2780868729 @default.
• W4210715759 hasConcept C2991741193 @default.
• W4210715759 hasConcept C535046627 @default.
• W4210715759 hasConcept C71924100 @default.
• W4210715759 hasConceptScore W4210715759C126322002 @default.
• W4210715759 hasConceptScore W4210715759C141071460 @default.
• W4210715759 hasConceptScore W4210715759C142724271 @default.
• W4210715759 hasConceptScore W4210715759C168563851 @default.
• W4210715759 hasConceptScore W4210715759C197934379 @default.
• W4210715759 hasConceptScore W4210715759C204787440 @default.
• W4210715759 hasConceptScore W4210715759C27081682 @default.
• W4210715759 hasConceptScore W4210715759C2776149422 @default.
• W4210715759 hasConceptScore W4210715759C2776301958 @default.
• W4210715759 hasConceptScore W4210715759C2776877702 @default.
• W4210715759 hasConceptScore W4210715759C2777475103 @default.
• W4210715759 hasConceptScore W4210715759C2778661090 @default.
• W4210715759 hasConceptScore W4210715759C2779161974 @default.
• W4210715759 hasConceptScore W4210715759C2779324797 @default.
• W4210715759 hasConceptScore W4210715759C2780868729 @default.
• W4210715759 hasConceptScore W4210715759C2991741193 @default.

• next